Estamos no ar no ! Saiba mais

Mustang Bio

MBIO

Valor de mercado US$ 2,85 mi

0,3764 USD

-0,0097

2,51%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-2,51%

5 dias

-8,2%

1 mês

-24,72%

3 meses

-41,6%

6 meses

-50,15%

No acumulado do ano

-64,82%

1 ano

-75,24%

5 anos

-99,98%

10 anos

-99,99%

Sobre: Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Funcionários: 4

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 0%

Negativo 0%

MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks

VANCOUVER, British Columbia, June 09, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company commercializing AI-driven voice analytics for intoxication and fatigue detection, is pleased to announce the Company has completed the manufacture of and delivered its first prototype Edge AI Intoxication Detection Kiosks. The first prototypes are a hardware and software solution designed for office and industrial use to detect intoxication and fatigue and improve safety in the workplace.

MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.

This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising

IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection

Zacks Investment Research

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Dow Dips 1%; Mustang Bio Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Monday.

Dow Dips 1%; Mustang Bio Shares Spike Higher

This BlackRock stock just spiked over 300%

Shares of Mustang Bio (NASDAQ: MBIO) surged on Monday as investors responded to a significant approval from the Food and Drug Administration (FDA).

This BlackRock stock just spiked over 300%

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1).

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation (“AbbVie”), for $1.0 million.

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™